Łukasz Zandecki1,2, Marcin Sadowski3,4, Marianna Janion5,4, Jacek Kurzawski5, Marek Gierlotka6,7, Lech Poloński6, Mariusz Gąsior6. 1. 2nd Cardiology Clinic, Swietokrzyskie Cardiology Center, Kielce, Poland. lukasz.zandecki@gmail.com. 2. The Faculty of Medicine and Health Sciences, The Jan Kochanowski University, Kielce, Poland. lukasz.zandecki@gmail.com. 3. Department of Interventional Cardiology, Swietokrzyskie Cardiology Center, Kielce, Poland. 4. The Faculty of Medicine and Health Sciences, The Jan Kochanowski University, Kielce, Poland. 5. 2nd Cardiology Clinic, Swietokrzyskie Cardiology Center, Kielce, Poland. 6. 3rd Department of Cardiology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia in Katowice, Silesian Centre for Heart Diseases, Zabrze, Poland. 7. Department of Cardiology, University Hospital, Institute of Medicine, University of Opole, Poland.
Abstract
BACKGROUND: Nowadays, the majority of patients with myocardial infarction with ST-segment elevation (STEMI) are treated with primary percutaneous coronary interventions (PCI). In recent years, there have been ongoing improvements in PCI techniques, devices and concomitant pharmacotherapy. However, reports on further mortality reduction among PCI-treated STEMI patients remain inconclusive. The aim of this study was to compare changes in management and mortality in PCI-treated STEMI patients between 2005 and 2011 in a real-life setting. METHODS: Data on 79,522 PCI-treated patients with STEMI from Polish Registry of Acute Coronary Syndromes (PL-ACS) admitted to Polish hospitals between 2005 and 2011 were analyzed. First, temporal trends of in-hospital management in men and women were presented. In the next step, patients from 2005 and 2011 were nearest neighbor matched on their propensity scores to compare in-hospital, 30-day and 1-year mortality rates and in-hospital management strategies and complications. RESULTS: Some significant changes were noted in hospital management including shortening of median times from admission to PCI, increased use of drug-eluting stents, potent antiplatelet agents but also less frequent use of statin, beta-blockers and angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. There was a strong tendency toward preforming additional PCI of non-infarct related arteries, especially in women. After propensity score adjustment there were significant changes in inhospital but not in 30-day or 1-year mortality rates between 2005 and 2011. The results were similar in men and women. CONCLUSIONS: There were apparent changes in management and significant in-hospital mortality reductions in PCI-treated STEMI patients between 2005 and 2011. However, it did not result in 30-day or 1-year survival benefit at a population level. There may be room for improvement in the use of guideline-recommended pharmacotherapy.
BACKGROUND: Nowadays, the majority of patients with myocardial infarction with ST-segment elevation (STEMI) are treated with primary percutaneous coronary interventions (PCI). In recent years, there have been ongoing improvements in PCI techniques, devices and concomitant pharmacotherapy. However, reports on further mortality reduction among PCI-treated STEMI patients remain inconclusive. The aim of this study was to compare changes in management and mortality in PCI-treated STEMI patients between 2005 and 2011 in a real-life setting. METHODS: Data on 79,522 PCI-treated patients with STEMI from Polish Registry of Acute Coronary Syndromes (PL-ACS) admitted to Polish hospitals between 2005 and 2011 were analyzed. First, temporal trends of in-hospital management in men and women were presented. In the next step, patients from 2005 and 2011 were nearest neighbor matched on their propensity scores to compare in-hospital, 30-day and 1-year mortality rates and in-hospital management strategies and complications. RESULTS: Some significant changes were noted in hospital management including shortening of median times from admission to PCI, increased use of drug-eluting stents, potent antiplatelet agents but also less frequent use of statin, beta-blockers and angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. There was a strong tendency toward preforming additional PCI of non-infarct related arteries, especially in women. After propensity score adjustment there were significant changes in inhospital but not in 30-day or 1-year mortality rates between 2005 and 2011. The results were similar in men and women. CONCLUSIONS: There were apparent changes in management and significant in-hospital mortality reductions in PCI-treated STEMI patients between 2005 and 2011. However, it did not result in 30-day or 1-year survival benefit at a population level. There may be room for improvement in the use of guideline-recommended pharmacotherapy.
Authors: Matthijs A Velders; Stefan K James; Berglind Libungan; Giovanna Sarno; Ole Fröbert; Jörg Carlsson; Martin J Schalij; Per Albertsson; Bo Lagerqvist Journal: Am Heart J Date: 2014-02-26 Impact factor: 4.749
Authors: Amit K Hiteshi; Dong Li; Yanlin Gao; Andy Chen; Ferdinand Flores; Song Shou Mao; Matthew J Budoff Journal: Clin Cardiol Date: 2014-09-30 Impact factor: 2.882
Authors: Etienne Puymirat; Tabassome Simon; Philippe Gabriel Steg; François Schiele; Pascal Guéret; Didier Blanchard; Khalife Khalife; Patrick Goldstein; Simon Cattan; Laurent Vaur; Jean-Pierre Cambou; Jean Ferrières; Nicolas Danchin Journal: JAMA Date: 2012-09-12 Impact factor: 56.272
Authors: Leonardo De Luca; Marco Marini; Lucio Gonzini; Alessandro Boccanelli; Gianni Casella; Francesco Chiarella; Stefano De Servi; Antonio Di Chiara; Giuseppe Di Pasquale; Zoran Olivari; Giorgio Caretta; Laura Lenatti; Michele Massimo Gulizia; Stefano Savonitto Journal: J Am Heart Assoc Date: 2016-11-23 Impact factor: 5.501
Authors: C P Gale; V Allan; B A Cattle; A S Hall; R M West; A Timmis; H H Gray; J Deanfield; K A A Fox; R Feltbower Journal: Heart Date: 2014-01-16 Impact factor: 5.994
Authors: Anthony H Gershlick; Jamal Nasir Khan; Damian J Kelly; John P Greenwood; Thiagarajah Sasikaran; Nick Curzen; Daniel J Blackman; Miles Dalby; Kathryn L Fairbrother; Winston Banya; Duolao Wang; Marcus Flather; Simon L Hetherington; Andrew D Kelion; Suneel Talwar; Mark Gunning; Roger Hall; Howard Swanton; Gerry P McCann Journal: J Am Coll Cardiol Date: 2015-03-17 Impact factor: 24.094